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Abstract
Objective
Anti-TNF therapies have been highly efficacious in the management of rheumatoid arthritis
(RA), but 25–30% of patients do not show a significant clinical response. There is increasing
evidence that genetic variation at the Fc receptor FCGR2A is associated with the response
to anti-TNF therapy. We aimed to validate this genetic association in a patient cohort from
the Spanish population, and also to identify new genes functionally related to FCGR2A that
are also associated with anti-TNF response.
Methods
A total of 348 RA patients treated with an anti-TNF therapy were included and genotyped
for FCGR2A polymorphism rs1081274. Response to therapy was determined at 12 weeks,
and was tested for association globally and independently for each anti-TNF drug (inflixi-
mab, etanercept and adalimumab). Using gene expression profiles from macrophages ob-
tained from synovial fluid of RA patients, we searched for genes highly correlated with
FCGR2A expression. Tag SNPs were selected from each candidate gene and tested for as-
sociation with the response to therapy.
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Results
We found a significant association between FCGR2A and the response to adalimumab
(P=0.022). Analyzing the subset of anti-CCP positive RA patients (78%), we also found a sig-
nificant association between FCGR2A and the response to infliximab (P=0.035). DHX32 and
RGS12were themost consistently correlated genes with FCGR2A expression in RA synovial
fluid macrophages (P<0.001). We found a significant association between the genetic varia-
tion at DHX32 (rs12356233, corrected P=0.019) and a nominally significant association be-
tween RGS12 and the response to adalimumab (rs4690093, uncorrected P=0.040). In the
anti-CCP positive group of patients, we also found a nominally significant association be-
tween RGS12 and the response to infliximab (rs2857859, uncorrected P=0.042).
Conclusions
In the present study we have validated the FCGR2A association in an independent popula-
tion, and we have identified new genes associated with the response to anti-TNF therapy in
RA.
Introduction
The introduction of Tumor Necrosis Factor (TNF) inhibitors has revolutionized the treatment
of rheumatoid arthritis (RA). In the clinical practice, anti-TNF alpha agents have made it possi-
ble to achieve a minimal inflammatory activity or even disease remission [1,2]. Despite their
clear efficacy in RA management, there is a substantial group of patients who will fail to re-
spond to this therapeutic approach [3]. The high costs of these therapies as well as the availabil-
ity of alternative biologic therapies in RA, clearly increase the need to identify markers of
response to anti-TNF agents [4].
Genetic variation has shown to influence many aspects of RA heterogeneity, including the
response to anti-TNF therapy [5,6]. Genome-wide association studies (GWAS) are a powerful
genetic analysis approach and have allowed the identification of new genomic regions associat-
ed with treatment response in RA [7,8]. Candidate-gene studies, although limited to the knowl-
edge of the biological pathways associated to a particular disease or trait, have also been
successful in identifying new candidate loci for the response to anti-TNF therapy [9]. One such
candidate gene is FCGR2A, encoding an Fc receptor mainly expressed in macrophages and
dendritic cells [10], and for which there is increasing evidence supporting its association to
anti-TNF therapy in RA [11].
Fc receptors for IgG immunoglobulins (FCGRs) are expressed in different immune cells but
predominantly in phacogytic cells like macrophages [12,13]. In these cells, FCGRs bind to ex-
tracellular IgG immunogloblins, and this binding can lead to either cell activation or repression
[13,14,15]. Consequently, the genetic variants that affect the activity of FCGRs [16,17,18,19],
could also influence the efficacy of immunoglobulin-based therapies like anti-TNF agents.
Infliximab, adalimumab and etanercept are the most commonly used anti-TNF agents in RA,
and are characterized by having an IgG1 Fc portion that can bind to FCGRs. Therefore, varia-
tions in the Fc binding affinity between the different anti-TNF agents could also influence the
response to these biological therapies [20,21,22].
FCGR2A (CD32A) SNP rs1801274 is a nonsynonymous polymorphism that leads to an
amino acid change at position 131 of the Fc receptor (i.e. R131H). This change in the protein
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sequence has shown to have important implications in the binding of the receptor to different
IgG subclasses [23,24]. Consequently, rs1801274 is a strong candidate for influencing the re-
sponse to IgG-based treatments, like anti-TNF agents. There is increasing evidence that varia-
tion at this SNP is associated with a differential response to anti-TNF therapy in RA [11,25].
Importantly, there is recent evidence that the association between FCGR2A and the clinical re-
sponse in RA could be dependent on the type of anti-TNF agent, with a significant association
in patients treated with infliximab [25,26] and a lack of association on etanercept-treated pa-
tients [26,27]. Despite the increasing evidence of a strong and differential genetic background
associated with patients positive for anti-cyclic citrullinated protein antibodies (anti-CCP, ~70–
80% of patients) [28,29,30], very few pharmacogenetic studies in RA have evaluated testing for
association in this subgroup of patients. If confirmed, this drug specific associations would be of
major relevance for RA. First, it would allow the identification of biological pathways that are
specifically targeted by each anti-TNF agent, and secondly, it could lead to the development of
new and more specific therapies and finally improve treatment personalization in RA.
The first objective of this study was to validate the association between FCGR2A and the
clinical response to the main anti-TNF agents infliximab, adalimumab and etanercept. Next,
we hypothesized that patients positive for anti-CCP antibodies could show stronger genetic as-
sociations to drug response. Also, we hypothesized that analyzing the gene expression correla-
tion of FCGR2A in a crucial cell type in RA, synovial fluid macrophage, we could identify new
candidate genes associated with anti-TNF response. Using a cohort of well-characterized RA
patients we have been able to validate and further characterize FCGR2A association, as well as
identify new candidate genes for anti-TNF response in RA.
Materials and Methods
Study population
A total of 348 RA patients that had received an anti-TNF therapy (infliximab, etanercept or
adalimumab) as their first biological treatment, were included in the present study. This patient
cohort was collected as part of the Immune-Mediated Inflammatory Disease Consortium
(IMIDC) [9], which includes a network of rheumatology departments from 12 university hos-
pitals from Spain. All patients fulfilled the 1987 American College of Rheumatology classifica-
tion criteria for RA [31] and had>2 years of follow-up since diagnosis. All recruited
individuals had an erosive disease defined as 1 erosions in, at least, 2 joint groups in hands
and/or feet. Only RA patients naïve to biologic therapies were included in this study. Patients
were Caucasian European born in Spain and with all four grandparents also born in Spain.
Informed consent was obtained from all participants and protocols were reviewed and ap-
proved by local institutional review boards. The present study was conducted according to the
Declaration of Helsinki principles.
The response to anti-TNF treatment was measured at week 12 following the EULAR treat-
ment response criteria [32]. For all patients, the DAS28 activity score [33] was measured at
baseline and after 12 weeks of anti-TNF treatment. According to the change in the DAS28
score and the endpoint DAS28, patients were categorized into good, moderate and none re-
sponders. As described previously, EULAR good and moderate responders were combined
into a single anti-TNF responder group [9].
FCGR2A correlated genes in synovial RA macrophages
The NCBI Gene Expression Omnibus database of microarray data [34] was used to identify
previous studies analyzing the gene expression profiles of macrophages obtained from synovial
fluid from rheumatoid arthritis patients. Using the terms "rheumatoid arthritis + macrophage
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+ synovial fluid" we found three different datasets (GSE49604, GSE11575 and GSE10500).
From these, we selected the gene expression profiles from RA CD14+ synovial macrophages
obtained by positive selection (i.e. GSE49604 and GSE10500). The gene expression profiles
from RA macrophages generated by in vitro differentiation of blood monocytes (GSE11575
dataset) was not considered in this study. The selected gene expression data was processed and
analyzed using the R statistical software [35] and the Bioconductor repository packages (www.
bioconductor.org). The details on dataset selection, data preprocessing and correlation analyses
are given in the Supporting Information (S1 Protocol). The correlation between FCGR2A
gene expression and the genes expressed in synovial fluid macrophages was analyzed using
the statistical test based on Pearson's product moment correlation. A significance threshold of
α = 0.001 was considered to select the genes most strongly correlated with FCGR2A.
DNA collection, SNP selection and genotyping
Whole blood samples were obtained from 348 RA patients and genomic DNA was extracted
using the Chemagic Magnetic Separation Module I (Perkin Elmer, US). The FCGR2A polymor-
phism previously associated with the response to anti-TNF therapy, SNP rs1801274
(FCGR2A-R131H), was analyzed in the cohort of RA patients using the TaqMan Real-Time
PCR platform (Life Technologies, US) with the C___9077561_20 predesigned assay.
Tag SNPs for DHX32 and RGS12 genes were selected using the genetic information from
the Caucasian European cohort (CEU) sequenced in the 1,000 Genomes Project (1KGP) [36].
Briefly, the dense SNP genotype generated from the 1KGP data from the sequences of the two
genes +/- 5 kb was downloaded. Using the Haploview genetic analysis tool (v4.2) [37] we iden-
tified the most relevant haplotype blocks in each gene and we selected the corresponding
tagSNPs. Additional details on the haplotype analysis and tagSNP selection are given in the
Supplementary Material (S1 Protocol). For DHX32 association analysis we selected tagSNP
rs12356233 (chromosome 10, pb 127,534,930), and for RGS12 locus we selected tagSNP
rs2857859 (pb 3,322,140) and rs4690093 (pb 3,412,196). Genotyping was performed with the
TaqMan RTCR technology (Life Technologies, US) using predesigned assays
C__31490226_30, C__26934339_10 and C__11283507_10 for rs12356233, rs2857859 and
rs4690093 genotyping, respectively.
For all Taqman analyses RTPCR thermal conditions were as follows: 50ºC for 2 min and
95ºC for 10 min, followed by 40 cycles of 92ºC for 15 s and 60ºC for 1 min. The PCR assay and
point fluorescent readings were performed using an ABI PRISM 7900HT sequence detection
system (Life Technologies, USA). Genotyping error was determined by re-genotyping 20% of
the patients (<1% genotyping error).
Statistical analysis
The association of the FCGR2A SNP rs1801274 with treatment response was performed using
Fisher’s exact test. Given that the association between DHX3 and RGS12 SNPs and response to
anti-TNF therapy was novel, we used the allelic chi-square test [38]. All statistical tests were
performed using the R statistical software version 3.0.1 (www.R-project.org).
Results
Study population
A total of 348 RA patients treated with anti-TNF agents were included. The patients had a
mean (±SD) age at diagnosis of 43.5 years (±12.6), and an average disease duration of 10.2
years (±8.3). From these, 126 patients had been treated with infliximab, 95 with adalimumab
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and 127 with etanercept. The complete clinical features of the patient cohort are shown in
Table 1.
Association of FCGR2A with anti-TNF response
Comparing FCGR2A genotype frequencies between the global cohort of anti-TNF therapy re-
sponders and non-responders, we found no significant association (P = 0.15, Table 2). When
analyzing the association within each different anti-TNF agent, we found a statistically signifi-
cant association between FCGR2A and the clinical response to adalimumab (P = 0.022,
Table 2). In infliximab-treated patients, we did not observe a statistically significant association
(P = 0.11), while in etanercept-treated patients we found no evidence of association with
FCGR2A SNP (P = 0.96).
RA patients that are positive for anti-cyclic citrullinated protein antibodies (anti-CCP),
have shown to have a differential and much stronger genetic background compared to anti-
CCP negative patients [28,29,30]. Based on this observation, we explored the FCGR2A associa-
tion with the response to anti-TNF therapy in the anti-CCP positive group of patients only
(78% in our cohort) (Table 3). Analyzing each treatment separately, we found that FCGR2A
SNP was significantly associated to the response of both adalimumab and infliximab (P = 0.047
and P = 0.035, respectively). By contrast, we found no association between FCGR2A and the
clinical response to etanercept (P = 1).
Identification and analysis of FCGR2A functionally-related genes
We identified two microarray-based studies in RA analyzing the transcriptome of synovial
macrophages (GSE49604 and GSE1050, n = 8 samples each). In both studies, synovial macro-
phages were isolated from the synovial fluid by positive CD14+ selection. In each study we
found one gene showing a consistent correlation with FCGR2A (P< 0.001). In GSE49604
study we found DEAH (Asp-Glu-Ala-His) box polypeptide 32 gene (DHX32) levels to be strong-
ly associated to FCGR2A gene expression, while in GSE1050 RA study we found regulator of G-
Table 1. Epidemiological and Clinical Features of the Patient Study Cohort.
Variable All (n = 348) Inﬂiximab (n = 126) Adalimumab (n = 95) Etanercept (n = 127)
Female, n (%) 287 (82.4) 107 (84.9) 76 (80.0) 104 (81.8)
Age at diagnosis (years) 43.5 ± 12.6 43.1 ± 11.6 45.9 ± 12.6 42.2 ± 13.3
Disease duration (years) 10.2 ± 8.3 10.1 ± 6.7 9.7 ± 9.1 10.8 ± 9.1
RF (+), n (%) 270 (77.8) 96 (76.1) 72 (76.6) 102 (80.3)
Anti-CCP (+), n (%) 261 (77.9) 87 (72.5) 79 (85.8) 95 (77.2)
Erosions, n (%) 314 (90.2) 115 (91.3) 85 (89.5) 114 (89.7)
Smokers, n (%) 148 (42.7) 52 (41.6) 43 (45.2) 43 (45.7)
Previous DMARDs 2.7 ± 1.7 3.1 ± 1.7 2.0 ± 1.4 2.7 ± 1.6
Concomitant corticoids, n (%) 182 (52.3) 64 (50.8) 49(51.6) 69 (54.3)
DAS28 (mean+/-SD), baseline 5.6 ± 1.1 5.6 ± 1.1 5.3 ± 1.0 5.7 ± 1.2
DAS28 (mean+/-SD), 12 weeks 3.9 ± 1.4 4.3 ± 1.4 3.5 ± 1.2 3.9 ± 1.5
ΔDAS28 (mean+/-SD) 1.6 ± 1.3 1.4 ± 1.3 1.7 ± 1.2 1.7 ± 1.4
EULAR Responders, n(%) 261(75%) 88 (70%) 76 (80%) 97 (76%)
EULAR Non-Responders, n(%) 87 (25%) 38 (30%) 19 (20%) 30 (24%)
Except where indicated otherwise, values are the mean ±SD. RF: rheumatoid factor; Anti-CCP: anti-citrullinated protein antibodies; DMARDs: disease-
modifying antirheumatic drugs; ΔDAS28; delta DAS28 (DAS28 baseline—DAS28 endpoint); EULAR: European League Against Rheumatism response,
where Good and Moderate EULAR responders were merged into a single Responder category.
doi:10.1371/journal.pone.0122088.t001
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protein signaling 12 gene (RGS12) to correlate significantly with FCGR2A levels (S1 Fig). DH32
was found to positively correlate with FCGR2A (average r2 = 0.93) and RGS12 to correlate neg-
atively with FCGR2A expression (average r2 = -0.96).
For each functionally-related gene we selected tagSNPs and performed an association test
with the clinical response to anti-TNF therapy in the RA patient cohort (Table 4). Analyzing
Table 2. Genotype frequencies of the FCGR2A polymorphism rs1801274 according to the clinical response at week 12.
Anti-TNF agent Genotype Responders n(%) Non-responders n(%) P-valuea OR(95%CI)
All (n = 348)
AA 67 (25.7) 25 (28.7) - -
AG 143 (54.8) 38 (43.7) - -
GG 51 (19.5) 24 (27.6) 0.15 1.1(0.78–1.56)
Inﬂiximab (n = 126)
AA 23 (26.1) 16 (42.1) - -
AG 49 (55.7) 14 (36.8) - -
GG 16 (18.2) 8 (21.1) 0.11 0.76(0.44–1.32)
Adalimumab (n = 95)
AA 21 (27.6) 3 (15.8) - -
AG 40 (52.6) 6 (31.6) - -
GG 15 (19.7) 10 (52.6) 0.022 2.54(1.19–5.4)
Etanercept (n = 127)
AA 23 (23.7) 6 (20) - -
AG 54 (55.7) 18 (60) - -
GG 20 (20.6) 6 (20) 0.96 1.06(0.6–1.9)
aFisher's exact test; OR: Odds ratio using allele G as reference.
doi:10.1371/journal.pone.0122088.t002
Table 3. Genotype frequencies of the FCGR2A polymorphism rs1801274 in anti-CCP positive RA patients according to the clinical response at
week 12.
Anti-TNF agent Genotype Responders n(%) Non-responders n(%) P-valuea OR (95%CI)
All (n = 261)
AA 52 (26.8) 21 (31.3) - -
AG 104 (53.6) 26 (38.8) - -
GG 38 (19.6) 20 (29.9) 0.079 1.12(0.76–1.66)
Inﬂiximab (n = 87)
AA 15 (24.6) 13 (50) - -
AG 36 (59) 8(30.8) - -
GG 10 (16.4) 5 (19.2) 0.035 0.62(0.32–1.22)
Adalimumab (n = 79)
AA 18 (30) 3(15.8) - -
AG 29 (48.3) 6 (31.6) - -
GG 13 (21.7) 10 (52.6) 0.047 2.56(1.18–5.54)
Etanercept (n = 95)
AA 19 (26) 5(22.7) - -
AG 39 (53.4) 12 (54.5) - -
GG 15 (20.5) 5 (22.7) 1 1.12(0.57–2.19)
aFisher's exact test; ANTI-CCP: anti-citrullinated protein antibodies; OR: Odds ratio using allele G as reference.
doi:10.1371/journal.pone.0122088.t003
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all anti-TNF agents together, we found no association between DHX32 or RGS12 SNPs with
the clinical response at week 12. However, when analyzing each treatment separately, we found
a significant association between DHX32 SNP rs12356233 with the response to adalimumab
(corrected P = 0.019). We also found a nominally significant association between RGS12 SNP
rs4690093 and the response to adalimumab (uncorrected P = 0.040), but this was no longer sig-
nificant after multiple test correction. When analyzing the anti-CCP positive group of RA pa-
tients (Table 5), rs12356233 was still still significantly associated with adalimumab response
(corrected P = 0.028), and RGS12 SNP rs4690093 was also associated at the nominal level only
(P = 0.044). Importantly, in this group of RA patients we also found a nominally significant as-
sociation between RGS12 SNP rs2857859 and the response to infliximab (uncorrected
P = 0.042). This association was not significant after multiple test correction.
Discussion
Anti-TNF agents have been a major success in RA treatment, significantly improving the prog-
nosis of many patients. There is, however, a group of RA patients that does not respond signifi-
cantly to this therapeutic approach. Consequently, there is a major need to identify biomarkers
that can help predict anti-TNF response and therefore guide anti-TNF therapy. In the present
study we have used a cohort of RA patients from the Spanish population to validate the associa-
tion between FCGR2A and anti-TNF agents infliximab, adalimumab and etanercept. Also, we
have identified the genes most strongly correlated with FCGR2A expression in synovial fluid
macrophages from RA studies, and we have found an association between these new, function-
ally-related genes with the response to anti-TNF therapy.
In our patient cohort we have found, for the first time, that FCGR2A is significantly associat-
ed with the response to infliximab in anti-CCP positive RA patients. Anti-CCP antibodies are
Table 4. DHX32 and RGS12 association with clinical response in RA patients according to anti-TNF therapy.
All anti-TNF Inﬂiximab Adalimumab Etanercept
SNP (gene) Minor Allele Major Allele MAF OR(95%CI) P OR(95%CI) P OR(95%CI) P OR(95%CI) P
rs12356233 (DHX32) G A 0.39 1.01(0.71–1.43) 0.96 0.65(0.37–1.15) 0.14 2.7(1.3–5.61) 0.0064* 0.85(0.47–1.56) 0.61
rs2857859 (RGS12) T C 0.3 0.87(0.59–1.28) 0.48 0.8(0.43–1.48) 0.48 0.98(0.45–2.15) 0.96 0.89(0.47–1.71) 0.73
rs4690093 (RGS12) G A 0.29 0.75(0.51–1.12) 0.16 0.95(0.52–1.71) 0.85 0.4(0.17–0.98) 0.04 0.88(0.44–1.76) 0.71
MAF: minor allele frequency in all RA patients; OR: odds ratio; CI: odds ratio conﬁdence interval; P: nominal signiﬁcance in association test with clinical
response at week 12.
*signiﬁcant (P<0.05) after multiple test correction.
doi:10.1371/journal.pone.0122088.t004
Table 5. DHX32 and RGS12 association with clinical response in anti-CCP positive RA patients according to anti-TNF therapy.
All anti-TNF Inﬂiximab Adalimumab Etanercept
SNP (gene) Minor Allele Major Allele MAF OR(95%CI) P OR(95%CI) P OR(95%CI) P OR(95%CI) P
rs12356233 (DHX32) G A 0.39 1.09(0.73–1.64) 0.66 0.85(0.42–1.7) 0.64 2.65(1.25–5.6) 0.0095* 0.7(0.35–1.42) 0.32
rs2857859 (RGS12) T C 0.29 0.64(0.4–1.03) 0.062 0.4(0.17–0.99) 0.042 1.01(0.45–2.25) 0.99 0.68(0.31–1.48) 0.33
rs4690093 (RGS12) G A 0.3 0.85(0.55–1.32) 0.46 1.13(0.57–2.24) 0.73 0.4(0.16–0.99) 0.049 1.06(0.48–2.31) 0.89
MAF: minor allele frequency in all anti-CCP RA patients; OR: odds ratio; CI: odds ratio conﬁdence interval; P: nominal signiﬁcance in association test with
clinical response at week 12.
*signiﬁcant (P<0.05) after multiple test correction.
doi:10.1371/journal.pone.0122088.t005
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known to bind to citrullinated antigens expressed in the synovial joint like filaggrin, and lead to
the formation of immune complexes which are powerful activators of the immune response
[39]. FCGR2A receptor has been shown to be key in the internalization of immune complexes
by phagocytic cells and consequently, could influence citrullinated peptide presentation by
HLA proteins and the subsequent activation of autorreactive T cells [40]. In this context, differ-
ences in the affinity of FCGR2A for citrullinated immune complexes could be counteracting
the beneficial effect of ADCC by inducing a major response to citrullinated autoantigens. The
results of this study, therefore, support the importance of anti-CCP antibodies in the FCGR2A-
mediated response to anti-TNF agents.
The genetic analysis of genes functionally related to FCGR2A in synovial macrophages from
RA patients, has lead to the identification of two new genes, DHX32 and RGS12 with the re-
sponse to anti-TNF therapy. DHX32 gene encodes for a putative RNA helicase, and has been
associated with lymphocyte differentiation and activation [41,42,43,44]. Importantly, RNA
helicases have also shown to be important in innate immunity inactivation of viral RNA [45],
and there is an increasing evidence that deregulation in this pathogen-sensing pathways could
contribute to the development of autoimmunity, including RA [46,47,48,49]. Together, these
results support the contribution of innate immunity in the differential response to anti-
TNF therapies.
RGS12 encodes for a member of the 'regulator of G protein signaling' gene family although
its biological still role remains to be characterized. Transcriptomic analysis on mouse mono-
cyte progenitor cells activated with Receptor Activator of NF-kappa-B (RANKL) have shown a
high induction of RGS12 gene [50]. RGS12 was shown to be highly and specifically expressed
in human osteoclasts, and the inhibition of RGS12 in mouse monocyte cultures impaired
RANKL-mediated differentiation to osteoclasts. These results suggest that RGS12 could partici-
pate in the macrophage to osteoclast transition, and therefore contribute to bone erosion and
disease activity in RA.
Like most genetic studies for drug response, the present study has limitations. Issues like the
uncertainty on the true genetic model underlying FCGR2A association, the definition of clinical
response or the presence of environmental or genetic interactions could have reduced the sta-
tistical power of the study. For example, analyzing only those patients with a more extreme
clinical response (i.e. EULAR good vs. none responders), only the FCGR2A association with
adalimumab in all patients is still significant (S1 and S2 Tables). In this case, discarding the
EULAR moderate group of patients, which is also the most frequent type of response (i.e.
>40% of anti-TNF treated patients), clearly reduces the statistical power to identify the genetic
associations. Also, from the observed genotype FCGR2A frequencies, there is no obvious gene
dosage effect. However, in a complex trait like anti-TNF response there is likely to be a poly-
genic component, with multiple risk genes of moderate to low effect size where genetic models
are more difficult to characterize. The presence of interaction effects can also limit our ability
to fully characterize the present pharmacogenetic association. In anti-CCP positive RA pa-
tients, smoking has shown to strongly interact withHLA-DRB1 genotypes in the risk to develop
the disease [51]. In our cohort of anti-CCP positive RA patients we did not find a significant in-
teraction between FCGR2A and smoking status (data not shown). Finally, the identification of
new anti-TNF response genes using gene expression profiles is clearly subject to isolating the
relevant cell type where the gene is expressed as well as the methodological approach used to
characterize the gene expression profiles. However, the association of genetic variants in
DHX32 and RGS12 loci associated with anti-TNF response, strongly supports the role of these
two new genes in RA pathophysiology.
In the present study, we confirm the association between FCGR2A and the response to anti-
TNF therapy. Also, using transcriptomic data from synovial fluid macrophages from RA
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studies, we have identified two genes, DHX32 and RGS12, strongly correlated with FCGR2A ex-
pression. Analyzing variants in these two new candidate genes, we have found new genetic as-
sociations with treatment response. The results of this study demonstrate a complex genetic
basis for anti-TNF response and are an important advance in the understanding of the molecu-
lar mechanisms associated with the response to these therapies.
Supporting Information
S1 Fig. Significantly correlated genes with FCGR2A in synovial macrophages. Plots of the
two probes measuring FCGR2A expression in SMPA and SMPB microarray studies with re-
spect to the most significantly correlated genes (P< 0.001, DHX32 in SMPA and RGS12 in
SMPB). The red line depicts the linear regression model of each gene against
FCGR2A expression.
(TIFF)
S1 Protocol. Includes the detailed description of the synovial macrophage microarray data-
set selection, data preprocessing and association analysis. It also includes details on the
methodology used to select tagSNPs for each gene, DHX32 and RGS12, functionally associated
with FCGR2A.
(DOCX)
S1 Table. FCGR2A polymorphism frequencies according to the EULAR extreme clinical re-
sponse.
(DOCX)
S2 Table. FCGR2A polymorphism frequencies in anti-CCP positive RA patients according
to the EULAR clinical extreme response.
(DOCX)
Acknowledgments
We thank the patients and clinical specialists collaborating in the IMID Consortium
for participation.
Author Contributions
Conceived and designed the experiments: GAP JT AFN AJ SM. Performed the experiments:
GAP AAMLL RT. Analyzed the data: GAP AA AJ SM. Contributed reagents/materials/analy-
sis tools: JT AFN FB IGA JDC JMMA BFG AO HC AE RT. Wrote the paper: GAP JT AFN FB
IGA JDC JMMA BFG AO HC AE AJ SM.
References
1. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LHD, Funovits J, et al. (2011) American College of
Rheumatology/European League Against Rheumatism provisional definition of remission in rheuma-
toid arthritis for clinical trials. Arthritis Rheum 63: 573–586. doi: 10.1002/art.30129 PMID: 21294106
2. Smolen JS, Aletaha D (2006) What should be our treatment goal in rheumatoid arthritis today? Clin Exp
Rheumatol 24 Suppl 43: S-7–13. PMID: 17083756
3. Salliot C, Finckh A, Katchamart W, Lu Y, Sun Y, Bombardier C, et al. (2011) Indirect comparisons of the
efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate re-
sponse to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor
agent: a meta-analysis. Ann Rheum Dis 70: 266–271. doi: 10.1136/ard.2010.132134 PMID: 21097801
4. van den Broek M, Visser K, Allaart CF, Huizinga TWJ (2013) Personalized medicine: predicting re-
sponses to therapy in patients with RA. Curr Opin Pharmacol 13: 463–469. doi: 10.1016/j.coph.2013.
03.006 PMID: 23578763
FCGR2A Pathway Association with Anti-TNF Response
PLOS ONE | DOI:10.1371/journal.pone.0122088 April 7, 2015 9 / 12
5. Emery P, Dorner T (2011) Optimising treatment in rheumatoid arthritis: a review of potential biological
markers of response. Ann Rheum Dis 70: 2063–2070. doi: 10.1136/ard.2010.148015 PMID:
22039166
6. Burska AN, Roget K, Blits M, Soto Gomez L, van de Loo F, Hazelwood LD, et al. (2014) Gene expres-
sion analysis in RA: towards personalized medicine. Pharmacogenomics J 14: 93–106. doi: 10.1038/
tpj.2013.48 PMID: 24589910
7. Cui J, Stahl EA, Saevarsdottir S, Miceli C, Diogo D, Trynka G, et al. (2013) Genome-wide association
study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in
rheumatoid arthritis. PLoS Genet 9: e1003394. doi: 10.1371/journal.pgen.1003394 PMID: 23555300
8. Krintel SB, Palermo G, Johansen JS, Germer S, Essioux L, Benayed R, et al. (2012) Investigation of
single nucleotide polymorphisms and biological pathways associated with response to TNFalpha inhibi-
tors in patients with rheumatoid arthritis. Pharmacogenet Genomics 22: 577–589. doi: 10.1097/FPC.
0b013e3283544043 PMID: 22569225
9. Acosta-Colman I, Palau N, Tornero J, Fernandez-Nebro A, Blanco F, Gonzalez-Alvaro I, et al. (2013)
GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response
in rheumatoid arthritis. Pharmacogenomics 14: 727–734. doi: 10.2217/pgs.13.60 PMID: 23651021
10. Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN (2014) The function of Fcgamma recep-
tors in dendritic cells and macrophages. Nat Rev Immunol 14: 94–108. doi: 110.1038/nri3582. Epub
2014 Jan 1021. PMID: 24445665
11. Montes A, Perez-Pampin E, Narvaez J, Canete JD, Navarro-Sarabia F, Moreira V, et al. (2014) Associ-
ation of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis. Phar-
macogenet Genomics 24: 238–245. doi: 10.1097/FPC.0000000000000042 PMID: 24667440
12. Ivan E, Colovai AI (2006) Human Fc receptors: critical targets in the treatment of autoimmune diseases
and transplant rejections. Hum Immunol 67: 479–491. PMID: 16829303
13. Siberil S, Dutertre CA, Boix C, Bonnin E, Menez R, Stura E, et al. (2006) Molecular aspects of human
FcgammaR interactions with IgG: functional and therapeutic consequences. Immunol Lett 106: 111–118.
PMID: 16797726
14. Ravetch JV, Lanier LL (2000) Immune inhibitory receptors. Science 290: 84–89. PMID: 11021804
15. Nimmerjahn F, Ravetch JV (2008) Fcgamma receptors as regulators of immune responses. Nat Rev
Immunol 8: 34–47. PMID: 18064051
16. ZhangW, Gordon M, Schultheis AM, Yang DY, Nagashima F, AzumaM, et al. (2007) FCGR2A and
FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing
metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 25: 3712–3718.
PMID: 17704420
17. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. (2008) Immunoglobulin G
fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with
HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26: 1789–1796. doi: 10.1200/JCO.2007.14.
8957 PMID: 18347005
18. WengWK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently
predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21: 3940–3947. PMID:
12975461
19. Paiva M, Marques H, Martins A, Ferreira P, Catarino R, Medeiros R (2008) FcgammaRIIa polymor-
phism and clinical response to rituximab in non-Hodgkin lymphoma patients. Cancer Genet Cytogenet
183: 35–40. doi: 10.1016/j.cancergencyto.2008.02.001 PMID: 18474295
20. Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR, et al. (2009) Differences in binding
and effector functions between classes of TNF antagonists. Cytokine 45: 124–131. doi: 10.1016/j.cyto.
2008.11.008 PMID: 19128982
21. Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN (2014) The function of Fcγ receptors in
dendritic cells and macrophages. Nat Rev Immunol 14: 94–108. doi: 10.1038/nri3582 PMID: 24445665
22. Mimoto F, Kadono S, Katada H, Igawa T, Kamikawa T, Hattori K (2014) Crystal structure of a novel
asymmetrically engineered Fc variant with improved affinity for FcγRs. Mol Immunol 58: 132–138. doi:
10.1016/j.molimm.2013.11.017 PMID: 24334029
23. Dijstelbloem HM, van deWinkel JG, Kallenberg CG (2001) Inflammation in autoimmunity: receptors for
IgG revisited. Trends Immunol 22: 510–516. PMID: 11525942
24. Bruhns P (2012) Properties of mouse and human IgG receptors and their contribution to disease mod-
els. Blood 119: 5640–5649. doi: 5610.1182/blood-2012-5601-380121. Epub 382012 Apr 380125.
PMID: 22535666
25. Canete JD, Suarez B, Hernandez MV, Sanmarti R, Rego I, Celis R, et al. (2009) Influence of variants of
Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League
FCGR2A Pathway Association with Anti-TNF Response
PLOS ONE | DOI:10.1371/journal.pone.0122088 April 7, 2015 10 / 12
Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
Ann Rheum Dis 68: 1547–1552. doi: 1510.1136/ard.2008.096982. Epub 092008 Oct 096917. PMID:
18930989
26. Montes A, Perez-Pampin E, Narvaez J, Canete JD, Navarro-Sarabia F, Moreira V, et al. (2014) Associ-
ation of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis. Phar-
macogenet Genomics 24: 238–245. doi: 10.1097/FPC.0000000000000042 PMID: 24667440
27. Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J, et al. (2004) The influence of genetic varia-
tion in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis
with methotrexate or etanercept. Arthritis Rheum 50: 2750–2756. PMID: 15457442
28. Padyukov L, Seielstad M, Ong RT, Ding B, Ronnelid J, SeddighzadehM, et al. (2011) A genome-wide
association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheuma-
toid arthritis. Ann Rheum Dis 70: 259–265. doi: 210.1136/ard.2009.126821. Epub 122010 Dec
126814. PMID: 21156761
29. Kurreeman F, Liao K, Chibnik L, Hickey B, Stahl E, Gainer V, et al. (2011) Genetic basis of autoantibody
positive and negative rheumatoid arthritis risk in a multi-ethnic cohort derived from electronic health rec-
ords. Am J HumGenet 88: 57–69. doi: 10.1016/j.ajhg.2010.1012.1007 PMID: 21211616
30. Bossini-Castillo L, de Kovel C, Kallberg H, van 't Slot R, Italiaander A, Coenen M, et al. (2014) A ge-
nome-wide association study of rheumatoid arthritis without antibodies against citrullinated peptides.
Ann Rheum Dis 14: 2013–204591.
31. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. (1988) The American
Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis
Rheum 31: 315–324. PMID: 3358796
32. van Gestel AM, Haagsma CJ, van Riel PL (1998) Validation of rheumatoid arthritis improvement criteria
that include simplified joint counts. Arthritis Rheum 41: 1845–1850. PMID: 9778226
33. Prevoo ML, van 't Hof MA, Kuper HH, van LeeuwenMA, van de Putte LB, van Riel PL, et al. (1995)
Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a
prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38: 44–48. PMID:
7818570
34. Barrett T, Edgar R (2006) Gene expression omnibus: microarray data storage, submission, retrieval,
and analysis. Methods Enzymol 411: 352–369. PMID: 16939800
35. Team RC (2013) R: A Language and Environment for Statistical Computing. ( R Foundation for Statisti-
cal Computing, Vienna, 2009). doi: 10.3758/s13428-013-0330-5 PMID: 23519455
36. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, et al. (2012) An integrated
map of genetic variation from 1,092 human genomes. Nature 491: 56–65. doi: 10.1038/nature11632
PMID: 23128226
37. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype
maps. Bioinformatics 21: 263–265. Epub 2004 Aug 2005. PMID: 15297300
38. Zondervan KT, Cardon LR (2004) The complex interplay among factors that influence allelic associa-
tion. Nat Rev Genet 5: 89–100. PMID: 14735120
39. Kuhn KA, Kulik L, Tomooka B, Braschler KJ, ArendWP, RobinsonWH, et al. (2006) Antibodies against
citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest 116:
961–973. PMID: 16585962
40. Takai T (2002) Roles of Fc receptors in autoimmunity. Nat Rev Immunol 2: 580–592. PMID: 12154377
41. AbdelhaleemM (2002) The novel helicase homologue DDX32 is down-regulated in acute lymphoblas-
tic leukemia. Leuk Res 26: 945–954. PMID: 12163057
42. Alli Z, Chen Y, Abdul Wajid S, Al-Saud B, AbdelhaleemM (2007) A role for DHX32 in regulating T-cell
apoptosis. Anticancer Res 27: 373–377. PMID: 17352256
43. Alli Z, Nam EH, Beimnet K, AbdelhaleemM (2005) The activation-induced expression of DHX32 in Jur-
kat T cells is specific and involves calcium and nuclear factor of activated T cells. Cell Immunol 237:
141–146. PMID: 16414036
44. AbdelhaleemM, Sun TH, Ho M (2005) DHX32 expression suggests a role in lymphocyte differentiation.
Anticancer Res 25: 2645–2648. PMID: 16080506
45. Meylan E, Tschopp J (2006) Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral
responses. Mol Cell 22: 561–569. PMID: 16762830
46. Baccala R, Gonzalez-Quintial R, Lawson BR, Stern ME, Kono DH, Beutler B, et al. (2009) Sensors of
the innate immune system: their mode of action. Nat Rev Rheumatol 5: 448–456. 410.1038/
nrrheum.2009.1136. Epub 2009 Jul 1014. doi: 10.1038/nrrheum.2009.136 PMID: 19597511
FCGR2A Pathway Association with Anti-TNF Response
PLOS ONE | DOI:10.1371/journal.pone.0122088 April 7, 2015 11 / 12
47. Narendra SC, Chalise JP, Hook N, MagnussonM (2014) Dendritic cells activated by double-stranded
RNA induce arthritis via autocrine type I IFN signaling. J Leukoc Biol 95: 661–666. 610.1189/
jlb.0613320. Epub 0612013 Dec 0613324. doi: 10.1189/jlb.0613320 PMID: 24304616
48. Mitoma H, Hanabuchi S, Kim T, Bao M, Zhang Z, Sugimoto N, et al. (2013) The DHX33 RNA helicase
senses cytosolic RNA and activates the NLRP3 inflammasome. Immunity 39: 123–135. 110.1016/j.
immuni.2013.1007.1001. Epub 2013 Jul 1018. doi: 10.1016/j.immuni.2013.07.001 PMID: 23871209
49. Mathews RJ, Robinson JI, Battellino M,Wong C, Taylor JC, Eyre S, et al. (2014) Evidence of NLRP3-
inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome
complex in relation to susceptibility to RA and response to anti-TNF treatment. Ann RheumDis 73:
1202–1210. 1210.1136/annrheumdis-2013-203276. Epub 202013 May 203217. doi: 10.1136/
annrheumdis-2013-203276 PMID: 23687262
50. Yang S, Li YP (2007) RGS12 is essential for RANKL-evoked signaling for terminal differentiation of os-
teoclasts in vitro. J Bone Miner Res 22: 45–54. PMID: 17042716
51. Lundstrom E, Kallberg H, Alfredsson L, Klareskog L, Padyukov L (2009) Gene-environment interaction
between the DRB1 shared epitope and smoking in the risk of anti-citrullinated protein antibody-positive
rheumatoid arthritis: all alleles are important. Arthritis Rheum 60: 1597–1603. 1510.1002/art.24572.
doi: 10.1002/art.24572 PMID: 19479873
FCGR2A Pathway Association with Anti-TNF Response
PLOS ONE | DOI:10.1371/journal.pone.0122088 April 7, 2015 12 / 12
